Not yet taking people in ItalyPhase 1
Testing TT125-802 for Relapsed or Refractory Multiple Myeloma
Tests TT125-802, alone or with other drugs, in adults with multiple myeloma.
Plain-language title generated from the registry record
Registry title: A Phase 1 Study of TT125-802 as Monotherapy and in Combination with Pomalidomide
and Dexamethasone in Participants with Multiple Myeloma
Key facts
- Where
- Bologna and Milan, ItalySee the 2 sites
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma that came back or stopped responding to treatment. It tests TT125-802 alone and with pomalidomide and dexamethasone.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Relapsed and refractory multiple myeloma (the cancer came back or no longer responds to treatment).
Read by machine on 9 November 2026.
Where in Italy
- Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere ScientificoBologna, ItalyNot yet recruiting
- Ospedale San Raffaele S.r.l.Milan, ItalyNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorTrial details
- Who runs it
- TOLREMO therapeutics AG
- Trial code
- EU 2025-523536-39-00
- Record updated
- 28 August 2026